BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PSI-938: Additional Phase I data

Data from 10 treatment-naïve patients with HCV genotype 1 infection enrolled in the fourth cohort of the placebo-controlled Phase I NUCLEAR trial showed that once-daily 300 mg PSI-938 plus once-daily 400 mg PSI-7977 led to reductions in HCV RNA to below the limit of detection (<15 IU/mL) in 1 of 8 patients by day 7 and in 5 of 8 patients by day 14. Additionally, all 8 patients who received the...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >